Stephen Michael Kelsey, Senior Advisor to the Chief Executive Officer of Revolution Medicines, Inc. (NASDAQ:RVMD), filed a Form 4 on September 15, 2026, disclosing option exercises and open-market sales of common stock executed on September 11, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercises: Kelsey exercised two stock options, acquiring 52,500 shares at $42.45 and 40,031 shares at $40.74 on September 11, 2026.
  • Shares sold: A total of 92,531 shares were sold across eight separate transactions at weighted average prices ranging from $198.5502 to $205.8075 per share.
  • 10b5-1 plan: All transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Kelsey on June 12, 2026.
  • Remaining ownership: Following all reported transactions, Kelsey directly beneficially owned 291,876 shares of common stock, including 76,251 restricted stock units.
  • Option disposition: The $42.45 strike option (52,500 shares) was fully exercised and no shares remain; 88,069 shares remain under the $40.74 strike option expiring March 1, 2035.
  • Reporting person role: Kelsey is identified in the filing as Senior Advisor to the Chief Executive Officer.

Kelsey's Option Exercises and Share Sales at Revolution Medicines on September 11, 2026

According to the filing, Kelsey exercised two stock options on September 11, 2026. The first, with an exercise price of $42.45, covered 52,500 shares and was described as fully vested. The second, with an exercise price of $40.74, covered 40,031 shares from a grant with a vesting commencement date of March 1, 2025, under which one forty-eighth of the total shares vest on each monthly anniversary, with the remaining 88,069 shares still outstanding under that option following the transaction.

On the same date, the filing discloses that Kelsey disposed of 92,531 shares of common stock across eight sale transactions. The weighted average prices reported were $198.5502, $200.1145, $200.7769, $201.7507, $203.0606, $203.8726, $204.8427, and $205.8075 per share. Each sale group was executed in multiple trades within defined price ranges, and the filing states that Kelsey will provide full per-price detail to the SEC, the issuer, or a security holder upon request.

After all reported transactions, Kelsey's direct beneficial ownership stood at 291,876 shares, which the filing notes includes 76,251 restricted stock units. The filing was signed by Jack Anders as attorney-in-fact for Stephen Michael Kelsey and submitted on September 15, 2026.

What Was Disclosed

The Form 4 reports two stock option exercises and eight share sale transactions by Revolution Medicines' Senior Advisor to the CEO on September 11, 2026, all conducted under a pre-established Rule 10b5-1 trading plan, with 291,876 shares remaining directly held afterward.